Displaying results 1 - 2 of 2
Clear search
Mestag Therapeutics extends seed financing to $45 million and welcomes new investors
Mestag Therapeutics, a breakthrough inflammatory disease and immuno-oncology company, has announced the closing of its oversubscribed Seed extension, bringing the total Seed round to $45 million.
Newborn bio business Mestag Therapeutics raises $11m seed cash
A new Cambridge UK BioMedTech business fighting inflammatory disease and cancer has launched with $11 million seed cash from healthcare backers SV Health Investors and Johnson & Johnson Innovation.